Alkermes (ALKS) vs Kiniksa Pharmaceuticals International (KNSA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Kiniksa Pharmaceuticals International (KNSA) has outperformed Alkermes (ALKS) over the past year, gaining 104.5% versus a gain of 33.9%. Over five years, KNSA leads with a +580.9% price change compared with +30.9% for ALKS. Alkermes is the larger company by market cap ($6.95 billion vs $6.08 billion), about 1.1 times the size, while Kiniksa Pharmaceuticals International is growing revenue faster (+60.1% vs -5.2%).
On valuation, Alkermes trades at a lower forward P/E (22.9x vs 48.2x for Kiniksa Pharmaceuticals International). Alkermes converts more of its revenue into profit, with a net margin of 16.4% versus 8.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALKS | KNSA |
|---|---|---|
| Share price | $41.45 | $77.96 |
| Market cap | $6.95B | $6.08B |
| 1-day change | -0.49% | +1.13% |
| YTD return | +48.12% | +88.99% |
| 1-year return | +33.91% | +104.51% |
| 5-year return | +30.87% | +580.87% |
| P/E ratio (TTM) | 109.07 | 78.75 |
| Forward P/E | 22.92 | 48.20 |
| EPS (TTM) | $0.38 | $0.99 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.48B | $677.56M |
| Revenue growth (YoY) | -5.25% | +60.09% |
| Net income (latest FY) | $241.66M | $59.01M |
| Gross margin | 86.69% | 88.54% |
| Operating margin | 17.21% | 11.40% |
| Net margin | 16.37% | 8.71% |
| 52-week high | $55.67 | $82.94 |
| 52-week low | $27.00 | $35.20 |
| Distance from 52-week high | -25.55% | -6.00% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +36.47% | +25.71% |
| Average volume | 1.83M | 589.58K |
| Shares outstanding | 167.76M | 48.29M |
| Employees | 2,050 | 366 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KNSA has outperformed ALKS by 70.6 percentage points over the past year.
- Alkermes trades at a higher earnings multiple (109.1x vs 78.7x trailing P/E).
- Alkermes is more profitable, keeping 16.4 cents of every revenue dollar as net income versus 8.7 cents for Kiniksa Pharmaceuticals International.
- Kiniksa Pharmaceuticals International grew revenue faster in its latest fiscal year (+60.09% vs -5.25%).
- The two companies sit in different sectors: Alkermes in Health Care and Kiniksa Pharmaceuticals International in Healthcare.
About Alkermes
ALKS stock →Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,050 employees
About Kiniksa Pharmaceuticals International
KNSA stock →Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis.
Healthcare · Drug Manufacturers - Specialty & Generic · 366 employees
ALKS vs KNSA FAQ
Which is bigger, Alkermes or Kiniksa Pharmaceuticals International?
Alkermes (ALKS) is larger, with a market capitalization of $6.95B compared with $6.08B for Kiniksa Pharmaceuticals International (KNSA).
Which stock has performed better over the past year, ALKS or KNSA?
KNSA returned +104.51% over the past 12 months, compared with +33.91% for ALKS (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ALKS or KNSA?
KNSA has the lower trailing P/E at 78.7, versus 109.1 for ALKS. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Alkermes and Kiniksa Pharmaceuticals International in the same industry?
No. Alkermes is in the Health Care sector, while Kiniksa Pharmaceuticals International is in Healthcare.